Octapharma develops and manufactures high-purity coagulation factor concentrates for patients with bleeding disorders.
These plasma products are produced to the highest standards, using the latest technology, in state-of-the-art manufacturing facilities to ensure the most advanced solutions are available to patients globally.
"Bleeding disorder" is a general term for a wide range of medical problems that lead to poor blood clotting and continuous bleeding, including:
~von Willebrand disease (VWD)
In people with such disorders, clotting factors like Factor VIII, Factor IX or von Willebrand factor (VWF) are missing or don't work as they should. This causes these people to bleed for a longer time than those whose blood factor levels are normal. Early on-demand or prophylactic therapy that replaces the missing coagulation factor is able to effectively control or prevent acute bleeding in this group of patients.
|Cat. No.||Product Name||CAS No.||Information|
A highly potent and selective platelet activating factor (PAF) antagonist; inhibits PAF-induced aggregation of rabbit and human platelets with IC50s of 33 nM and 55 nM respectively; potently protects mice from death induced by PAF and due to anaphylactic shock with ED50 of 2.1 and 2.6 ug/kg (i.v.), respectively; also reverses PAF-induced hypotension and endotoxin-induced hypotension in rats.
No.1378 West Wenyi Road, Yuhang District, HangZhou, Zhejiang, China